Catalysts / ARQT
Upcoming FDA decisions and readouts we track for Arcutis Biotherapeutics, each with the filing that announced it.
FreeBioList tracks 1 upcoming catalyst for Arcutis Biotherapeutics (ARQT, listed on Nasdaq). It concerns ZORYVE (roflumilast) cream 0.05% (Atopic dermatitis in infants aged 3–24 months).
First on the list: the PDUFA date for ZORYVE (roflumilast) cream 0.05% (Atopic dermatitis in infants aged 3–24 months), dated 23 Feb 2027.
The row links to an SEC filing (8-K or 6-K). It has been verified by a person reading the filing itself, most recently on 11 Sep 2026. The methodology page explains each status.
Background reading: What a PDUFA date is, and why the FDA doesn't publish them.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| Arcutis Biotherapeutics ARQT · Nasdaq | ZORYVE (roflumilast) cream 0.05% | Atopic dermatitis in infants aged 3–24 months | 23 Feb 2027 in 139d |
PDUFA date | Verified | 8-K exhibit 99.1 ↗ | No |
FreeBioList